Online citations, reference lists, and bibliographies.
← Back to Search

Co-delivery Of SiRNA And An Anticancer Drug For Treatment Of Multidrug-resistant Cancer.

M. Saad, O. Garbuzenko, T. Minko
Published 2008 · Medicine, Materials Science

Cite This
Download PDF
Analyze on Scholarcy
Share
AIMS To develop a novel nanomedicine approach for the treatment of multidrug-resistant (MDR) cancer by combining an anticancer drug and suppressors of cellular resistance within one multifunctional nanocarrier-based delivery system (NDS). MATERIALS & METHODS The NDS consisted of cationic liposomes (carrier, 100-140 nm), doxorubicin (DOX, anticancer drug), siRNA targeted to MRP1 and BCL2 mRNA (suppressors of pump and nonpump cellular-resistance, respectively). The resulting approximately 500 nm complex has a zeta potential of +4 mV. RESULTS & DISCUSSION The NDS provides an effective co-delivery of DOX and siRNA as well as cell-death induction and suppression of cellular resistance in MDR lung cancer cells. CONCLUSION We demonstrate NDS-enhanced efficiency of chemotherapy to a level that cannot be achieved by applying its components separately.
This paper references
Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
D. E. Lopes de Menezes (2000)
10.1016/J.JCONREL.2006.06.010
In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug.
R. I. Pakunlu (2006)
Dysregulation of apoptosis in cancer.
John Calvin Reed (1998)
10.1093/CARCIN/21.3.485
Apoptosis in cancer.
S. Lowe (2000)
10.1016/J.NANO.2007.01.002
DOTAP/UDCA vesicles: novel approach in oligonucleotide delivery.
B. Ruozi (2007)
10.1126/SCIENCE.281.5381.1322
The Bcl-2 protein family: arbiters of cell survival.
J. Adams (1998)
10.1201/9780203492321
Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids
R. Mahato (2009)
10.1159/000125560
Nonviral gene delivery.
H. Akita (2008)
10.2174/1389450043345443
Molecular targeting of drug delivery systems to cancer.
T. Minko (2004)
10.1023/A:1018959029186
Comparison of the Anticancer Effect of Free and HPMA Copolymer-Bound Adriamycin in Human Ovarian Carcinoma Cells
T. Minko (2004)
10.2174/187152006778699095
New generation of liposomal drugs for cancer.
T. Minko (2006)
10.1016/0092-8674(93)90509-O
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death
Zoltán N. Oltval (1993)
10.1023/A:1023839319950
Targeted Proapoptotic LHRH-BH3 Peptide
S. Dharap (2004)
10.1007/978-0-387-76554-9_10
Multifunctional Nanotherapeutics for Cancer
T. Minko (2008)
10.3892/OR.14.5.1337
Targeted adriamycin delivery to MXT-B2 metastatic mammary carcinoma cells by transferrin liposomes: effect of adriamycin ADR-to-lipid ratio.
L. A. Lopez-Barcons (2005)
10.1021/bc8000722
Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery.
M. L. Patil (2008)
10.1016/S0009-9120(99)00026-0
Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer.
S. Kassim (1999)
10.1016/J.PROGPOLYMSCI.2005.09.004
Polymer-drug conjugates: Progress in polymeric prodrugs
J. Khandare (2006)
10.1016/S0960-9822(06)00410-6
Regulation of apoptosis by BH3 domains in a cell-free system
S. Cosulich (1997)
10.1124/jpet.105.098855
Novel Polymeric Prodrug with Multivalent Components for Cancer Therapy
J. Khandare (2006)
Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer.
J. Kigawa (1998)
10.1016/S0361-090X(03)00067-9
Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense.
T. Minko (2003)
10.1080/10611860701349364
In vivo transfection rat small intestine K-cell with pGIP/Ins plasmid by DOTAP liposome
A. Palizban (2007)
10.1021/MP060014X
JNK1 as a molecular target to limit cellular mortality under hypoxia.
S. Betigeri (2006)
10.2174/138161206775201965
An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy.
K. Takara (2006)
Functional comparison of single- and double-stranded mdr1 antisense oligodeoxynucleotides in human ovarian cancer cell lines.
V. Jekerle (2005)
10.1080/10611860701794353
Polymeric nanoparticles for cancer therapy
S. Parveen (2008)
10.1016/S0168-3659(03)00209-8
Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides.
S. Dharap (2003)
10.2174/138955708783744074
Strategies for in vivo siRNA delivery in cancer.
A. Sanguino (2008)
10.1016/S0168-3659(98)00186-2
Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line.
T. Minko (1999)
10.1021/MP070053O
Targeted proapoptotic anticancer drug delivery system.
P. Chandna (2007)
Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme.
H. Hatanaka (2001)
10.1093/ANNONC/10.SUPPL_5.S83
Multidrug resistance in non-small-cell lung cancer.
G. Scagliotti (1999)
10.1201/9780203492321.ch15
Mechanisms of cellular drug resistance and strategies to overcome it
T. Minko (2004)
10.1016/J.BBRC.2005.03.041
Cationic lipids enhance siRNA-mediated interferon response in mice.
Z. Ma (2005)
10.1023/A:1022687617318
Simultaneous Modulation of Multidrug Resistance and Antiapoptotic Cellular Defense by MDR1 and BCL-2 Targeted Antisense Oligonucleotides Enhances the Anticancer Efficacy of Doxorubicin
R. I. Pakunlu (2004)
10.1101/GAD.13.15.1899
BCL-2 family members and the mitochondria in apoptosis.
A. Gross (1999)
Targeted proapoptotic 17 LHRH - BH 3 peptide
SS Dharap (2003)
10.1016/J.JCONREL.2007.10.024
A fast and sensitive method for measuring the integrity of siRNA-carrier complexes in full human serum.
K. Buyens (2008)
10.1158/0008-5472.CAN-04-0001
Enhancement of the Efficacy of Chemotherapy for Lung Cancer by Simultaneous Suppression of Multidrug Resistance and Antiapoptotic Cellular Defense
R. I. Pakunlu (2004)
10.1042/BST0280386
Modulation of thyroid hormone receptor silencing function by co-repressors and a synergizing transcription factor.
M. Lutz (2000)
Polymeric 33 drugs
T Minko (2005)
10.1016/j.jconrel.2008.05.024
Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?
M. Saad (2008)
10.1073/PNAS.0504274102
Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.
S. Dharap (2005)
10.1615/CRITREVTHERDRUGCARRIERSYST.V23.I2.30
RNA-interference effectors and their delivery.
D. Putnam (2006)
10.1124/jpet.105.094243
Molecular Targeting of BCL2 and BCLXL Proteins by Synthetic BCL2 Homology 3 Domain Peptide Enhances the Efficacy of Chemotherapy
S. Dharap (2006)
10.2174/156720106778559029
Particulate systems as adjuvants and carriers for peptide and protein antigens.
M. Liang (2006)
Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs.
A. Aszalos (1998)
Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells.
Hao Wu (2003)
10.1016/J.CANLET.2006.03.001
Jasmonates in cancer therapy.
E. Flescher (2007)
10.1074/jbc.274.19.13298
Bak BH3 Peptides Antagonize Bcl-xL Function and Induce Apoptosis through Cytochrome c-independent Activation of Caspases*
E. P. Holinger (1999)
Glutamyl Cysteine Synthetase UpRegulates Glutathione and Multidrug Resistance-associated Protein in Patients with Chemoresistant Epithelial Ovarian Cancer
Junzo (2005)
10.1177/030089160809400218
Delivery of Small Interfering RNA. A Review and an Example of Application to a Junction Oncogene
Anne-Laure Ramon (2008)
10.1002/BIOF.5520170111
Multidrug resistance‐associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate
L. Homolya (2003)
10.1042/BST0280051
Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins.
R. Lutz (2000)
10.1073/pnas.0602515103
Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1
R. Watts (2006)
Small Interfering RNA-induced Suppression of MDR 1 ( P-Glycoprotein ) Restores Sensitivity to Multidrug-resistant Cancer Cells 1
Hao Wu (2003)
10.1158/1078-0432.CCR-07-2020
Nonviral Nanoscale-Based Delivery of Antisense Oligonucleotides Targeted to Hypoxia-Inducible Factor 1α Enhances the Efficacy of Chemotherapy in Drug-Resistant Tumor
Y. Wang (2008)
Nonviral gene 52 delivery
H Akita (2000)
10.1158/0008-5472.CAN-05-1779
Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase.
J. Zhou (2006)
10.1046/J.1359-4117.2003.01075.X
Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice.
D. E. Lopes de Menezes (2003)
10.1007/s004080000091
Relationship Between Chemotherapy Response of Small Cell Lung Cancer and P-glycoprotein or Multidrug Resistance-Related Protein Expression
T.-C. Hsia (2002)
Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
M. Ihnat (1999)
10.1158/0008-5472.CAN-07-5810
Targeted delivery of small interfering RNA: approaching effective cancer therapies.
K. Pirollo (2008)
10.1074/jbc.M611019200
Glutathione Export during Apoptosis Requires Functional Multidrug Resistance-associated Proteins*
C. Hammond (2007)
Advances in cancer gene therapy: tumor-targeted delivery of therapeutic pDNA, siRNA, and dsRNA nucleic acids.
E. Wagner (2007)
10.1021/LA0631668
Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility.
A. Schroeder (2007)
10.1007/s00232-006-0009-2
Role of Cholesterol, DOTAP, and DPPC in Prostasome/Spermatozoa Interaction and Fusion
C. Palmerini (2006)



This paper is referenced by
10.1039/c9cc01446b
A multifunctional persistent luminescent nanoprobe for imaging guided dual-stimulus responsive and triple-synergistic therapy of drug resistant tumor cells.
Fengxia Su (2019)
10.1080/1061186X.2019.1648478
Role of therapeutic agents on repolarisation of tumour-associated macrophage to halt lung cancer progression
Hibah M Aldawsari (2019)
10.1007/978-3-319-08084-0_10
Nano-Platforms for Tumor-Targeted Delivery of Nucleic Acid Therapies
Arun K Iyer (2014)
10.1002/smll.201202485
Nanoparticles for gene delivery.
H. Tian (2013)
10.2174/138920112800624418
Nanocarriers for the simultaneous co-delivery of therapeutic genes and anticancer drugs.
N. Choudhury (2012)
10.1021/acs.bioconjchem.5b00146
Co-delivery of protein and small molecule therapeutics using nanoparticle-stabilized nanocapsules.
C. S. Kim (2015)
10.1007/S11434-013-6030-9
Nanocarriers for siRNA delivery to overcome cancer multidrug resistance
Qingshuo Meng (2013)
10.1016/B978-0-444-62614-1.00014-4
PEGylated polymer micelles for anticancer drug delivery carrier
Masao Kamimura (2014)
10.1039/c9ra07894k
pH-sensitive CAP/SiO2 composite for efficient co-delivery of doxorubicin and siRNA to overcome multiple drug resistance
Zheng Cai (2020)
10.1016/j.ajps.2019.10.003
Enhanced anticancer effect of doxorubicin by TPGS-coated liposomes with Bcl-2 siRNA-corona for dual suppression of drug resistance
Yinghuan Li (2019)
10.1016/j.actbio.2015.09.029
Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense.
M. Sun (2015)
10.1039/c3cc47970f
Co-delivery of small interfering RNA using a camptothecin prodrug as the carrier.
Qiong Tang (2014)
10.1039/C8RA03375G
Co-delivery of anti-PLK-1 siRNA and camptothecin by nanometric polydiacetylenic micelles results in a synergistic cell killing
Manon Ripoll (2018)
10.1016/j.biomaterials.2011.11.079
Supramolecular assemblies in functional siRNA delivery: where do we stand?
Hamidreza M. Aliabadi (2012)
10.1007/s12013-015-0549-0
Combination Approach: the Future of the War Against Cancer
L. Chen (2015)
10.1016/j.jconrel.2019.01.025
Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers
O. Garbuzenko (2019)
10.1016/j.addr.2017.06.003
Nanoformulations for combination or cascade anticancer therapy.
L. Miao (2017)
10.7150/thno.4949
Cholesterol Derivatives Based Charged Liposomes for Doxorubicin Delivery: Preparation, In Vitro and In Vivo Characterization
Yu Nie (2012)
Multifunctional Natural Material-based Delivery Systems for Gene Therapy
Qiong Tang (2014)
10.2147/IJN.S86053
pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells
H. Chen (2015)
10.1016/B978-0-323-42866-8.00003-4
Lipid nanoparticles as non-viral vectors for siRNA delivery
R. Petrilli (2016)
10.1007/978-3-319-18045-8
Biomaterials in Regenerative Medicine and the Immune System
L. Santambrogio (2015)
10.5402/2012/247657
Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease
O. Simmons (2012)
10.7497/j.issn.2095-3941.2014.01.004
Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention
O. Garbuzenko (2014)
10.1016/j.addr.2013.08.004
Nanopreparations to overcome multidrug resistance in cancer.
N. Patel (2013)
10.4155/TDE.10.13
Nanoparticle-assisted combination therapies for effective cancer treatment.
C. Hu (2010)
10.2217/nnm.12.73
Efficient systemic delivery of siRNA by using high-density lipoprotein-mimicking peptide lipid nanoparticles.
Qiaoya Lin (2012)
10.1016/j.biomaterials.2010.11.061
The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
Nuo Cao (2011)
10.1021/bc5002714
Intracellular delivery of antisense peptide nucleic acid by fluorescent mesoporous silica nanoparticles.
Xing Ma (2014)
10.1016/j.biomaterials.2014.11.029
Synergism through combination of chemotherapy and oxidative stress-induced autophagy in A549 lung cancer cells using redox-responsive nanohybrids: a new strategy for cancer therapy.
Hsin-Yi Lu (2015)
10.1039/C6NJ02753A
Enhanced cytotoxicity by a benzothiazole-containing cisplatin derivative in breast cancer cells
Chaoqun You (2017)
10.1007/978-1-60761-609-2_19
LHRH-targeted nanoparticles for cancer therapeutics.
T. Minko (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar